Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.
NCT05282030
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
22
Enrollment
INDUSTRY
Sponsor class
Conditions
Renal Impairment
Interventions
DRUG:
tolebrutinib
Sponsor
Sanofi